Enveric Biosciences, Inc.: 5%+ holders

As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Enveric Biosciences, Inc. The largest reported stake is Armistice Capital, LLC's, at 9.99%. 16 filings are on record since September 24, 2025 (Schedule 13G, August 14, 2026).

Northstrive Fund II LP also filed stake reports on 2 other companies ↓

Sell to companies like Enveric Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-03 · Reporting person: Sio Capital Management, LLC · Sole voting: 0 · Shared voting: 330,000 · Sole dispositive: 0 · Shared dispositive: 330,000 · SCHEDULE 13G, 2026-11-03
• Filing 2026-08-14 · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 405,092 · Sole dispositive: 0 · Shared dispositive: 405,092 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: Lind Global Fund III LP · Sole voting: 49,366 · Shared voting: 0 · Sole dispositive: 49,366 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-13 · Reporting person: Ayrton Capital LLC · Sole voting: 111,145 · Shared voting: 0 · Sole dispositive: 111,145 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
• Filed 2026-05-15 · Holder: Easton Jeff · Percent: 7.87% · SCHEDULE 13G/A

Enveric Biosciences, Inc. has 16 Schedule 13D or 13G filings on record since 2025-09-24. 2 holders' latest filing reports 5% or more of common stock, par value, $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Enveric Biosciences, Inc. and the warning signs.

See Enveric Biosciences, Inc.'s free Snapshot Watch Enveric Biosciences, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Enveric Biosciences, Inc. and the records around it.

Enveric Biosciences, Inc. elsewhere on the record

• Company profile and every filing May 2026
• Form D filing May 2026
• Form D filing Feb 2026
• Who owns it

Companies that share a holder

• Northstrive Fund II LP also filed stake reports on 2 other companies: Bluejay Diagnostics, Inc. (Jun 2026), enVVeno Medical Corp (Feb 2026)
• Braeden Lichti also filed stake reports on 3 other companies: enVVeno Medical Corp (Sep 2026), PMGC Holdings Inc. (Jun 2026), Bluejay Diagnostics, Inc. (Jun 2026)
• AdvisorShares Trust also filed stake reports on 8 other companies: Neuphoria Therapeutics Inc. (Oct 2026), PSYENCE BIOMEDICAL LTD. (Oct 2026), Silo Pharma, Inc. (Jul 2026)

Want the whole picture on Enveric Biosciences, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Enveric Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Enveric Biosciences, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   21 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Enveric Biosciences, Inc. by CUSIP 29405E505 and gives its principal executive office as 245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA 02142 (SCHEDULE 13G, 2026-11-03).

What the percentages are based on

The percentages below are based on (i) 3,681,884 shares of Common Stock of the Issuer that were outstanding as of May 13, 2026; and (ii) 111,145 shares of Common Stock issuable on the exercise of the Warrants held by the Reporting Persons. The amount of shares outstanding was based upon a statement in the Issuer's Form 10-Q filed on May 15, 2026.Ayrton Capital LLC, SCHEDULE 13G/A, 2026-08-13

Timeline

Swipe the table sideways to see every column.

Questions about who owns Enveric Biosciences, Inc.

Who owns Enveric Biosciences, Inc.?

On this page, 2 holders' latest ownership filings report 5% or more of Enveric Biosciences, Inc.: Armistice Capital, LLC (9.99%, Schedule 13G, filed 2026-08-14) and Sio Capital Management, LLC (7.37%, Schedule 13G, filed 2026-11-03).

Who are the largest shareholders of Enveric Biosciences, Inc.?

By the share each holder's latest filing reports, the largest holders of Enveric Biosciences, Inc. on this page are Armistice Capital, LLC (9.99%) and Sio Capital Management, LLC (7.37%).

When did Armistice Capital, LLC buy into Enveric Biosciences, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G, filed 2026-08-14, reporting 9.99%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 16 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Enveric Biosciences, Inc.

Swipe the table sideways to see every column.

Enveric Biosciences, Inc.: every filing and event

Tools for this story

Each opens in a new tab, filled in for Enveric Biosciences, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Enveric Biosciences, Inc. is mentioned again
• Find former Enveric Biosciences, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes